Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Big Money Sentiment Index Falls in 2018 Q4 to 1.25

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Corporate Logo

“Big money” Positions

“Big money sentiment for Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) in Q4 2018 decreased to 1.25, revealed SEC filings. So its down -0.27, from 2018Q3’s 1.52. 40 active investment managers opened new or increased holdings, while 32 reduced and sold their positions in Tetraphase Pharmaceuticals Inc so the sentiment is negative. These funds own 22.30 million shares, that’s up from 21.44 million shares in 2018Q3. Funds holding Tetraphase Pharmaceuticals Inc in top 10 changed to 0 from 0 for the same number . 12 Investors Sold All; 20 Reduced Holdings; 25 increased stakes while 15 active investment managers bought stakes.

Biggest Tetraphase Pharmaceuticals Inc Shareholders

As of Q4 2018 Anson Funds Management Lp has 0.22% invested in Tetraphase Pharmaceuticals Inc. Tetraphase Pharmaceuticals Inc’s shareholder 683 Capital Management Llc owns 790,571 shares as of Q4 2018. Further, Tekla Capital Management Llc reported 859,322 shares in Tetraphase Pharmaceuticals Inc equivalent to 0.04% of its US long equity exposure. The Connecticut-based fund Quantitative Systematic Strategies Llc have invested about 0.02% of the investment manager’s stock portfolio in Tetraphase Pharmaceuticals Inc. The New York-based fund A.R.T. Advisors Llc holds 94,382 shares or 0.01% of their US long equity exposure.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections.The firm is valued at $58.58 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.Currently it has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

TTPH hit $1.09 during the last trading session after $0.05 change.Tetraphase Pharmaceuticals, Inc. is downtrending after having declined 52.42% since April 18, 2018. TTPH has 858,687 volume or 36.00% up from normal. TTPH underperformed by 56.79% the S&P 500.

Tiaa Cref Invest Ltd Co has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). 120,099 were reported by Citadel Advisors Limited Liability Corp. Manchester Mngmt Ltd Liability has 14,984 shs. Dow De invested 0.01% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Axa accumulated 99,000 shs or 0% of the stock. Macquarie Gru Ltd invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Invesco reported 53,787 shs. Gamco Invsts Et Al reported 50,000 shs. The Texas-based Bridgeway Cap Mgmt has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Legal & General Group Inc Public Ltd stated it has 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Savings Bank Of Ny Mellon has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Moreover, Pnc Finance Gp Inc has 0% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Tower Rech Limited Liability Company (Trc) holds 0% or 9,349 shs in its capital. 55,900 are owned by Alliancebernstein Limited Partnership. State Street invested in 0% or 1.25M shs.

Tetraphase Pharmaceuticals, Inc. registered $11,995 net activity with 0 buys and 1 insider sale since January 8, 2019.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings Coverage

Total analysts of 2 have positions in Tetraphase Pharmaceuticals (NASDAQ:TTPH) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since February 26, 2019 according to StockzIntelligence Inc Tetraphase Pharmaceuticals has 5 analyst reports. The company rating was maintained by H.C. Wainwright on Friday, March 15. On Friday, March 15 Piper Jaffray maintained Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) with “Buy” rating.

For more Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) news brought out briefly go to: Seekingalpha.com, Seekingalpha.com, Globenewswire.com, Seekingalpha.com or Businesswire.com. The titles are as follows: “Tetraphase launches eravacycline in U.S.; shares up 13% after hours – Seeking Alpha” brought out on October 11, 2018, “Is The Worst Over For Tetraphase Pharmaceuticals? – Seeking Alpha” on February 28, 2018, “Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVAâ„¢ in the United States – GlobeNewswire” with a publish date: October 11, 2018, “Tetraphase Pharmaceuticals to present XERAVA and TP-6076 data at IDWeek 2018 – Seeking Alpha” and the last “Tetraphase Pharmaceuticals to Present Data on Preclinical Activity of TP-2846 in Acute Myeloid Leukemia – Business Wire” with publication date: February 27, 2019.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.